Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment-Reference-Cited by-同舟云学术

Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment

Published:2015 Issue:9 Volume:62 Page:811-816
ISSN:0918-8959
Container-title:Endocrine Journal
language:en
Short-container-title:Endocr J

Author:

Endo Itsuro¹,Fukumoto Seiji²,Ozono Keiichi³,Namba Noriyuki³,Inoue Daisuke⁴,Okazaki Ryo⁴,Yamauchi Mika⁵,Sugimoto Toshitsugu⁵,Minagawa Masanori⁶,Michigami Toshimi⁷,Nagai Masaki⁸,Matsumoto Toshio²

Affiliation:

1. Department of Hematology, Endocrinology & Metabolism Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima 770-8503 Japan

2. Fujii Memorial Institute of Medical Sciences, Tokushima University, Tokushima 770-8503, Japan

3. Department of Pediatrics, Osaka University Graduate School of Medicine, Suita 565-0871, Japan

4. Third Department of Medicine, Teikyo University Chiba Medical Center, Ichihara 299-0111, Japan

5. Internal Medicine 1, Shimane University Faculty of Medicine, Izumo 693-8501, Japan

6. Department of Endocrinology, Chiba Children’s Hospital, Chiba 266-0007, Japan

7. Department of Bone and Mineral Research, Research Institute, Osaka Medical Center for Maternal and Child Health, Izumi 594-1101, Japan

8. Department of Public Health, Saitama Medical University Faculty of Medicine, Iruma 350-0495, Japan

Publisher

Japan Endocrine Society

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.jstage.jst.go.jp/article/endocrj/62/9/62_EJ15-0275/_pdf

Reference10 articles.

1. 1. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, et al. (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19: 429-435.

2. 2. Hori M, Shimizu Y, Fukumoto S (2011) Minireview: fibroblast growth factor 23 in phosphate homeostasis and bone metabolism. Endocrinology 152: 4-10.

3. 3. Hashimoto S, Fukutomi K, Nagai M, Nakamura Y, Yanagawa H, et al. (1991) [A method of interval estimation for number of patients in the nationwide epidemiological survey on intractable diseases]. Nihon Koshu Eisei Zasshi 38: 880-883 (In Japanese).

4. 4. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, et al. (2002) Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87: 4957-4960.

5. 5. Carpenter TO (1997) New perspectives on the biology and treatment of X-linked hypophosphatemic rickets. Pediatr Clin North Am 44: 443-466.

Cited by 136 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. X-linked hypophosphataemia;The Lancet;2024-08

2. Evaluation of dental manifestations in X-linked hypophosphatemia using orthopantomography;PLOS ONE;2024-07-26

3. Pretreatments to bonding on enamel and dentin disorders: a systematic review;Evidence-Based Dentistry;2024-07-23

4. Etiología de la hipofosfatemia en el adulto;Medicina Clínica;2024-07

5. Burosumab treatment of X-linked hypophosphatemia patients: interim analysis of the SUNFLOWER longitudinal, observational cohort study;JBMR Plus;2024-06-10